Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
NexImmune, Inc. NEXI
$0.31
-$0.02 (-7.04%)
На 18:04, 12 мая 2023
+974.19%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
8579827.00000000
-
week52high
3.00
-
week52low
0.20
-
Revenue
0
-
P/E TTM
0
-
Beta
2.30579600
-
EPS
-2.23000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 10:59
Описание компании
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Raymond James | Outperform | Outperform | 16 авг 2022 г. |
| Barclays | Overweight | Overweight | 16 авг 2022 г. |
| BTIG | Buy | 01 июн 2022 г. | |
| Barclays | Overweight | Overweight | 01 апр 2022 г. |
| Raymond James | Outperform | Outperform | 22 февр 2022 г. |
| Cantor Fitzgerald | Neutral | Overweight | 16 ноя 2022 г. |
| Raymond James | Market Perform | Outperform | 15 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Jones Kristi | A | 369778 | 296700 | 26 ноя 2022 г. |
| OELKE MATHIAS | A | 134023 | 126100 | 22 ноя 2022 г. |
| Trainer John | A | 186969 | 125200 | 22 ноя 2022 г. |
| BARER SOL J | A | 1817814 | 75000 | 17 ноя 2022 г. |
| BARER SOL J | A | 1742814 | 125000 | 16 ноя 2022 г. |
| Bertram Timothy | A | 61678 | 61678 | 13 июн 2022 г. |
| D'Angio Paul | A | 61678 | 61678 | 13 июн 2022 г. |
| BARER SOL J | A | 61678 | 61678 | 13 июн 2022 г. |
| Verstandig Grant | A | 61678 | 61678 | 13 июн 2022 г. |
| Roemer Alan S. | A | 61678 | 61678 | 13 июн 2022 г. |
Новостная лента
Why Is NexImmune (NEXI) Stock Down 4% Today?
InvestorPlace
20 янв 2023 г. в 09:04
NexImmune (NASDAQ: NEXI ) stock is falling on Friday as the immunotherapies company's shares come off of a recent high earlier this week. The NEXI stock rally started earlier this week and has seen the company's shares go through several rises and falls.
NexImmune to Present at the H.C. Wainwright 24th Annual Global Investment Conference
GlobeNewsWire
09 сент 2022 г. в 16:01
GAITHERSBURG, Md., Sept. 09, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Kristi Jones, Chief Executive Officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12 at 11:00 am ET.
NexImmune (NEXI) IND Gets Clearance for HPV-Related Cancer Drug
Zacks Investment Research
15 июл 2022 г. в 12:12
NexImmune (NEXI) gets FDA clearance for IND for drug for human papillomavirus (HPV)-related cancers.
Why Is NexImmune (NEXI) Stock Up 30% Today?
InvestorPlace
15 июл 2022 г. в 11:55
NexImmune appears to be making headway in the company's ongoing battle against HPV-related cancers -- and NEXI stock is heading higher today. The post Why Is NexImmune (NEXI) Stock Up 30% Today?
What Makes NexImmune, Inc. (NEXI) a New Buy Stock
Zacks Investment Research
10 июн 2022 г. в 13:33
NexImmune, Inc. (NEXI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).